Skip to main content
Dryad

LCA reports for Johnson & Johnson Innovative Medicine sponsored phase-2, 3, 4 clinical trials

Data files

Jan 31, 2025 version files 411.38 KB

Abstract

Objective: To calculate the global warming potential, in carbon dioxide (CO2) equivalent emissions, from all in-scope activities involved in phase-1, 2, 3, and 4 clinical studies spanning multiple disease areas

Design: Retrospective analysis

Data source:  Data collected by Johnson & Johnson Innovative Medicine during study conduct

Studies included:  Johnson & Johnson Innovative Medicine sponsored 77242113PSO2001 (ClinicalTrials.gov: NCT05364554), 42756493BLC2002 (ClinicalTrials.gov: NCT03473743), 54767414MMY3012 (ClinicalTrials.gov: NCT03277105), VAC18193RSV3006 (ClinicalTrials.gov: NCT05070546), R092670PSY3016 (ClinicalTrials.gov: NCT04072575), and 28431754DIA4032 (ClinicalTrials.gov: NCT04288778) clinical studies conducted between 2018-2023

Main outcome: measure CO2 equivalents (CO2e) for in-scope clinical trial activities calculated according to Intergovernmental Panel on Climate Change (IPCC) 2021 impact assessment methodology.